Voyager Reports Six-Month NHP Toxicology Data for Tau-Targeted AAV Gene Therapy in Alzheimer’s Disease

July 15, 2026 — Voyager Therapeutics presented six-month good laboratory practice toxicology data for VY1706, its investigational BBB-crossing AAV gene therapy targeting tau for Alzheimer’s disease…